Arcutis Biotherapeutics, Inc. (ARQT)

NASDAQ: ARQT · IEX Real-Time Price · USD
17.35
-0.16 (-0.91%)
Dec 5, 2022 4:00 PM EST - Market closed
-0.91%
Market Cap 1.07B
Revenue (ttm) 725,000
Net Income (ttm) -310.77M
Shares Out 57.09M
EPS (ttm) -4.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 542,493
Open 17.7
Previous Close 17.51
Day's Range 17.09 - 17.7
52-Week Range 13.59 - 27.4
Beta 0.44
Analysts Buy
Price Target 56.21 (+224.0%)
Earnings Date Nov 8, 2022

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ... [Read more]

Industry Biotechnology
IPO Date Jan 31, 2020
Employees 147
Stock Exchange NASDAQ
Ticker Symbol ARQT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for ARQT stock is "Buy." The 12-month stock price forecast is 56.21, which is an increase of 223.98% from the latest price.

Price Target
$56.21
(223.98% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovation...

3 hours ago - GlobeNewsWire

Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255

WESTLAKE VILLAGE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations...

11 hours ago - GlobeNewsWire

MyHealthTeam and Arcutis Biotherapeutics Launch New Social Network for People Living with Seborrheic Dermatitis

MySebDermTeam provides trusted connection, information, and support to accelerate diagnosis and treatment SAN FRANCISCO, Dec. 1, 2022 /PRNewswire/ -- MyHealthTeam , creator of the largest and fastest-gr...

4 days ago - PRNewsWire

Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaq...

WESTLAKE VILLAGE, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermato...

1 week ago - GlobeNewsWire

Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report

WESTLAKE VILLAGE, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermat...

2 weeks ago - GlobeNewsWire

Arcutis' ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

WESTLAKE VILLAGE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermato...

2 weeks ago - GlobeNewsWire

Arcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis Study

Arcutis Biotherapeutics (ARQT) reports positive top-line data from a phase III study of its lead candidate, roflumilast cream 0.15%, for treating atopic dermatitis.

2 weeks ago - Zacks Investment Research

CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream...

CORRECTION: In a press release issued earlier today under the same headline, please note that the p-value for WI-NRS should have been P

2 weeks ago - GlobeNewsWire

Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Der...

WESTLAKE VILLAGE, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovation...

2 weeks ago - GlobeNewsWire

Arcutis to Present at Upcoming Investor Conference

WESTLAKE VILLAGE, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermat...

3 weeks ago - GlobeNewsWire

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Misses Revenue Estimates

Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of -22.73% and 27.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for ...

3 weeks ago - Zacks Investment Research

Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update

WESTLAKE VILLAGE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations...

3 weeks ago - GlobeNewsWire

Arcutis to Report Third Quarter Financial Results

WESTLAKE VILLAGE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermat...

1 month ago - GlobeNewsWire

Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis

WESTLAKE VILLAGE, Calif., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermat...

1 month ago - GlobeNewsWire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovation...

2 months ago - GlobeNewsWire

Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and ...

WESTLAKE VILLAGE, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-derma...

2 months ago - GlobeNewsWire

Journal of the American Medical Association Publishes Roflumilast Cream 0.3% Results from Pivotal DERMIS-1 and -2 Pha...

WESTLAKE VILLAGE, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermat...

2 months ago - GlobeNewsWire

New Data from Arcutis' STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis Presented at E...

WESTLAKE VILLAGE, Calif. and MILAN, Italy, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovation...

2 months ago - GlobeNewsWire

LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million

First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science Ducentis lead pre-clinical asset DS-234 is being developed for the treatment ...

2 months ago - PRNewsWire

Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.

WESTLAKE VILLAGE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovatio...

2 months ago - GlobeNewsWire

New Data from Arcutis' Topical Roflumilast Clinical Program Presented at the European Academy of Dermatology and Vene...

WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-derma...

2 months ago - GlobeNewsWire

Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors

WESTLAKE VILLAGE, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-derma...

3 months ago - GlobeNewsWire

NEW CAMPAIGN FROM ARCUTIS AIMS TO EXPOSE THE IMPACT OF PSORIASIS ON PHYSICAL, MENTAL, AND EMOTIONAL WELLBEING

Launched during Psoriasis Action Month, campaign provides tips and tools for speaking about psoriasis with healthcare providers, family, and friends WESTLAKE VILLAGE, Calif. , Aug. 30, 2022 /PRNewswire/...

3 months ago - PRNewsWire

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

Wall Street Analysts Believe Arcutis Biotherapeutics, Inc. (ARQT) Could Rally 134%: Here's is How to Trade

The mean of analysts' price targets for Arcutis Biotherapeutics, Inc. (ARQT) points to a 134.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agr...

3 months ago - Zacks Investment Research